Secreted Frizzled-related protein 1 (SFRP1) encodes a member of a protein family that contains a cysteine-rich domain similar to the WNT-binding site of Frizzled receptors and regulates the WNT pathway. The WNT pathway is frequently altered in human cancers. We have de®ned the pattern of SFRP1 mRNA expression in the progression of breast cancer. We show that SFRP1 is expressed in the epithelial component of normal breast, in the in situ component of ductal carcinomas and is lost in more than 80% of invasive breast carcinomas except the medullary type. Loss of SFRP1 expression is correlated with the presence of hormonal receptors. Conversely, the maintenance of SFRP1 in carcinomas is correlated with the presence of lymphoplasmocytic stroma. No signi®cant association was observed between SFRP1 status and the level of apoptosis in tumoral cells. Oncogene (2001) 20, 5810 ± 5817.
Introduction
The multistep model of carcinogenesis in the breast suggests transition from normal to invasive carcinoma via a series of intermediate hyperplastic and neoplastic stages (Lakhani, 1999) . However, there is no clear association of these steps with genetic alterations, as in colon carcinomas (Vogelstein et al., 1988) . One approach to understanding the molecular basis of cancer is to identify dierences in gene expression between cancer cells and normal cells.
The short arm of chromosome 8 is a site of frequent genetic alterations in various tumors (Leach et al., 1996) . In sporadic breast carcinomas, these alterations include ampli®cation of oncogenes such as FGFR1 (Ugolini et al., 1999) , deletions (Leach et al., 1996; Ugolini et al., 1999; Yaremko et al., 1996) , and in one case translocation (Wang et al., 1999) . Based on the dierential expression assay of chromosome 8p11 ± 21 genes, we have recently identi®ed SFRP1 whose mRNA was reduced or absent in breast carcinomas (Ugolini et al., 1999) . We hypothesized that SFRP1 could be a tumor suppressor gene contributing to the genesis and/or the development of breast cancer.
SFRP1 (Secreted Frizzled-Related Protein 1) encodes one of the ®ve known members of a family of secreted proteins (SFRP/FRP/FRZB, see references at the web site: http://www.ana.ed.ac.uk/rnusse/frizzleds/frp.html) that contain a domain similar to the WNT-binding region of the Frizzled family of transmembrane receptors. As currently understood, WNT secreted factors bind to receptors of the Frizzled family on the cell surface. Through several cytoplasmic relay components, the signal is transduced to b-catenin, which then enters the nucleus and forms a complex with a member of the TCF (T-cell factor)/LEF (lymphoid enhancer factor) family of transcription factors to activate transcription of WNT target genes (Gumbiner, 1998; Zorn, 1997) . Competition between Frizzled and SFRP in binding to WNTs regulates the activation of the WNT pathway (Zorn, 1997) . Two recent studies provide evidence concerning mechanisms involved in WNT signaling by members of the SFRP family (Ba®co et al., 1999; U È ren et al., 2000) .
WNTs were ®rst identi®ed as mammary oncogenes, then as genes regulating cell-to-cell interactions during embryogenesis. Dysregulation of the WNT signaling pathway plays a role in cancer (Pennisi, 1998) . Several WNT pathway members are expressed in normal and tumoral mammary tissues (Dale et al., 1996) and may be involved in human breast cancer (Huguet et al., 1994) . Some of them have been implicated in the pathogenesis of colon cancer, hepatocellular carcinoma, and melanoma, including the tumor suppressor gene APC (Adenomatous Polyposis Coli), b-catenin (Morin et al., 1997) , and axin 1 (Satoh et al., 2000) . Direct target genes for transcriptional activation by the b-catenin/TCF complex have been identi®ed in human colon cancers. They include MYC (He et al., 1998) and CCND1, the gene coding for the cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 1999) , both playing important roles in breast cancer.
Little is known about the role of SFRPs in tumorigenesis. Upregulation of SFRP1 has been associated with apoptosis (Melkonyan et al., 1997; Zhou et al., 1998) , and downregulation has been found in breast tumors (Ugolini et al., 1999; Zhou et al., 1998) . SFRPs ectopic expression promotes growth and inhibits motility of malignant glioma cells (Roth et al., 2000) . To document the potential involvement of SFRP1 in breast cancer, we report a detailed analysis of SFRP1 expression using an in situ hybridization method that shows associations between SFRP1 lossof-expression and clinicopathological features of breast cancer. In particular, we show that SFRP1 may be involved in tumor progression and invasion and could be a novel and clinically useful breast tumor marker.
Results

SFRP1 expression is markedly absent or reduced in most invasive breast carcinomas
To determine if SFRP1 is dierentially expressed in dierent types of breast cancer or if it is stage-related, we used Northern blot and RNA in situ hybridization (ISH) analyses. Of the 40 carcinoma samples studied by RNA in situ hybridization (ISH), 21 had accompanying normal tissue (1 ± 13 lobular units per sample): in total, 73 normal lobular units were numbered, 98.6% of them were positive with SFRP1 expression in 90% of the glandular epithelium.
Northern blot analysis of SFRP1 expression One hundred and seven invasive breast tumors (81 ductal, of which four with predominant in situ component, 13 lobular, four tubular, three medullary, and two mixed ductal and lobular carcinomas) were analysed. Of these, 85 (79.5%) showed an altered SFRP1 mRNA expression as compared to normal breast. Representative results are shown in Figure 1 . Three groups of tumors were identi®ed depending on their SFRP1 expression status as assessed by expression ratio quanti®cation for tumors versus normal breast as previously described (Ugolini et al., 1999) : SFRP1 was normally expressed compared to the normal breast in 22 tumors (20.5%), signi®cantly underexpressed (expression ratios between 1/7 and 1/5) in 42 tumors (39.3%), and undetectable (expression ratios lower than 1/7) in 43 tumors (40.2%).
In situ hybridization analysis of SFRP1 expression To con®rm the absence of SFRP1 expression and to identify its putative correlation with histological type of breast tumors, we performed ISH on 30 selected samples: four SFRP1-negative tumors, 18 tumors with reduced SFRP1 expression, and eight tumors with normal expression. A strong expression was detected in the epithelial cells by the antisense SFRP1 probe but not in the stromal cells of the normal mammary gland (Figure 2a ). SFRP1 expression was also detected in the normal ducts adjacent to the tumors (Figure 2d ), and in some carcinoma samples as further described. Sense probes (negative controls) were negative for all tissues examined (see for examples Figure 2b ,f). SFRP1-negative expression found in Northern blot hybridization was con®rmed in all four cases. In 14 of the 18 tumors that expressed a reduced level of SFRP1 mRNA, no expression was detected in the tumoral tissue by ISH. In the other cases, SFRP1 expression was weak and sometimes detected in a small fraction of cells in the invasive component (Figure 2c ). SFRP1 mRNA was undetectable by ISH in three of the eight SFRP1-Northern blot positive tumors. These results show that in more than one-third of the tumors, SFRP1 expression revealed by Northern blot analysis was probably due to the labeling of adjacent normal breast component and not to the tumoral component ( Figure 2d) .
SFRP1 expression was then assessed by ISH in 10 ductal carcinomas already studied by Northern blot hybridization. There were three early stages (ductal in situ, the only frozen samples available for this experiment) and seven advanced stages (invasive ductal with predominant in situ component). In the three pure ductal carcinomas in situ (DCIS), SFRP1 expression was variable. In one DCIS, no SFRP1 expression was found as compared to adjacent normal breast ducts (Figure 1d ). In the two other DCIS, the expression of SFRP1 was found in a small fraction of tumor cells or in the epithelial cells located at the edge of the tumoral breast ducts (Figure 1e ). In six of the seven carcinomas (5284)). Ten mg of total RNA from each sample were sequentially hybridized with 32 P-labeled human SFRP1 and bactin human cDNA probes according to Church and Guilbert (1984) Oncogene SFRP1 in breast cancer F Ugolini et al of advanced stages, SFRP1 expression was found in the intraductal component and at the periphery of ducts, whereas the adjacent invasive component had lost all SFRP1 expression. Finally, no SFRP1 expression was found in the tumoral tissue for the remaining case. In conclusion, eight of 10 carcinomas (80%) were SFRP1-positive in the intraductal component, whereas the invasive component was SFRP1-negative in six of seven tumors (85.7%). It is also noteworthy that all 10 tumors were grade 3, and no correlation was found To evaluate the morphological type of the SFRP1-positive cells located at the periphery of the tumoral ducts, histochemical labeling was done on the same slides by using myoepithelial markers. No colocalization was found for SFRP1 and either alpha smooth muscle actin or calponin (data not shown). These results clearly indicated that SFRP1 is only present in the epithelial layer of the ducts and not in the myoepithelial cells.
Loss of SFRP1 expression is not observed in medullary breast carcinomas
By Northern blot analysis we noted that SFRP1 expression was normal in two out of the three medullary breast tumors tested and in the medullary carcinoma cell line, MDA-MB-157. To con®rm these observations, we collected a series of 20 medullary samples and checked mRNA expression by in situ hybridization. SFRP1 was expressed in the tumor cells of all medullary samples, and the expression pattern was either homogeneous (present in all tumoral cells) in 10 cases (Figure 1g ) or heterogeneous in the other 10 cases.
Apoptosis analysis
SFRP1 was found to be regulated through the cellcycle mechanism and accumulated in growth-arrested or apoptotic cells (Melkonyan et al., 1997; Zhou et al., 1998) . To investigate whether the modulation of SFRP1 expression is associated with dierences in apoptotic activity, TUNEL assays were done on 38 sections derived from samples for which the SFRP1 status was known (19 SFRP1-positive and 19 SFRP1-negative samples). Table 1 shows data on the apoptotic index (see Materials and methods section and Labat- Moleur et al., 1998) . Only stained cells that displayed an apoptotic morphology (cell shrinkage and chromatin condensation and/or nuclear condensation) were included, whereas necrotic areas were excluded from the analysis. TUNEL signals were detectable within the nuclei of the carcinoma cells. Figure 3 shows two representative cases of SFRP1-positive invasive breast carcinomas displaying low and high levels of apoptosis (upper and lower panel, respectively) . No statistically signi®cant relationship between the level of SFRP1 and apoptosis was observed, but a trend to a low level of apoptosis in SFRP1-negative cases could be noted (16 and nine cases of SFRP1-positive and -negative samples, respectively, Table 1 ).
Correlations between SFRP1 expression and clinicopathologic features in invasive breast cancers
The clinical details of the cohort of patients with ductal breast cancers included in this study and the statistical analysis are listed in Table 2 . Only two signi®cant associations were observed: First, the loss of SFRP1 mRNA was correlated with the presence of both hormonal receptors, i.e., estrogen (P=0.00004), and progesterone (P=0.0299) receptors. Second, the expression of SFRP1 was correlated with the presence of a moderate or marked lymphoplasmocytic stroma (P=0.0001). In addition, neither the presence nor the loss of SFRP1 expression was associated with a decrease in risk for both relapse or death from breast cancer (data not shown). 
Discussion
The development of breast cancer involves many types of genes that need to be activated or inactivated in order to promote malignancy. In this type of cancer, the sequential steps in gene alterations with respect to tumor progression are not clear and far less well understood than what is currently the best model of tumor progression, colorectal carcinoma. The identi®-cation of genetic alterations that take place in the transition between in situ and invasive ductal carcinomas is therefore important for understanding the progression of breast cancer (Lakhani, 1999) . We identi®ed SFRP1, a gene localized to the 8p11 chromosomal region, which displays loss of heterozygosity in breast cancers (Ugolini et al., 1999) . SFRP1 mRNA is normally expressed in the mammary gland, and is either dramatically reduced (expression ratios tumor versus normal breast tissue between 1/7 and 1/5) or completely lost in at least 80% of invasive breast carcinomas, whereas it is frequently positive in the in situ component of ductal carcinomas. SFRP1 loss is correlated with tumor progression but not with the pathological grade of breast tumors. Our results (Yaremko et al., 1996 , and references herein), suggesting that inactivation of tumor suppressor genes of this region participates in cancer progression. The loss of SFRP1 had no in¯uence on risk for relapse or death from breast cancer. However, the fact that SFRP1 expression is lost/reduced in a large fraction of tumors (80%) suggests that SFRP1 is one of the most frequent targets of alteration in breast cancer. Indeed, well-studied markers of breast carcinoma aggressiveness, such as ERBB2 and P53, are aected in less than 30% of breast carcinomas (Ingvarsson, 1999; Ross and Fletcher, 1999; Simpson and Page, 2000) . Although, in the absence of a good antibody, we do not have evidence that SFRP1 protein levels parallel the levels of mRNA, the frequent absence of SFRP1 mRNA in human invasive breast cancer suggests that this gene may be involved in tumor progression and invasion. It also suggests a potential use of this marker in diagnosis and as a therapeutic target in breast tumors.
In contrast, SFRP1 mRNA expression remains normal in medullary breast carcinomas. Medullary breast carcinomas constitute less than 5% of all breast cancers and are often associated with a better prognosis than the common forms of invasive breast carcinoma (Pedersen, 1997) . They are characterized by a predominantly syncytial growth pattern, and according to Ridol®'s histopathological criteria (Ridol® et al., 1977) two groups are de®ned, i.e., typical and atypical medullary carcinomas. p53 is the sole genetic defect described to date that is able to distinguish speci®cally medullary breast carcinoma (de Cremoux et al., 1999) . The present report demonstrates that SFRP1 expression is observed in the syncytial component of all medullary carcinomas, including the atypical variant. Based on this somewhat unique medullary breastspeci®c pattern, we believe that SFRP1 could also be an excellent candidate for a novel breast tumor biomarker. The fact that a lymphoplasmocytic stroma of both in®ltrating ductal and medullary carcinomas is always observed in the SFRP1-positive tumors suggests that SFRP1 expression could be associated directly or indirectly with the immune reaction.
Loss of SFRP1 mRNA is correlated with the presence of hormonal receptors. The estrogen receptor, an important regulator of growth and dierentiation of breast epithelial cells, can form a speci®c complex with another important regulator, cyclin D1 (Neuman et al., 1997; Zwijsen et al., 1997) leading to the activation of estrogen receptor transcriptional activity. Cyclin D1 encoded by CCND1 is a major regulator of the progression into the proliferative stage of the cell cycle (Sherr, 1996) . It has been identi®ed in human colon cancers as the direct activated target of the WNT/bcatenin signaling (Tetsu and McCormick, 1999) . While the clinical signi®cance of cyclin D1 in breast cancers remains highly controversial (Seshadri et al., 1996; van Diest et al., 1997) , CCND1 ampli®cation and overexpression is predominantly observed in hormone receptor-positive tumors in ductal in situ (Theillet et al., 1990; Vos et al., 1999) , and invasive breast cancers (Takano et al., 1999 , and references therein). In colorectal cancers, increase of cyclin D1 transcriptional activation results from the binding to LEF1 of elevated b-catenin levels caused by mutations in b-catenin or APC (Shtutman et al., 1999; Tetsu and McCormick, 1999) . We did not detect any b-catenin mutations in ®ve SFRP1-positive and three SFRP1-negative samples (data not shown). Furthermore, we did not observe any modi®cations in b-catenin mRNA levels either in carcinoma cell lines or in breast tumors as compared with their normal counterparts.
SFRP1 is a member of a group of soluble proteins, the soluble Frizzled-related proteins (SFRPs), also called secreted apoptosis-related proteins (SARPs) (Finch et al., 1997; Leyns et al., 1997; Rattner et al., 1997; Wang et al., 1997) . These proteins regulate the WNT pathway by binding to WNT proteins (Ba®co et al., 1999) . Importantly, SFRP1 has been shown to act as a modulator of WNT signaling (U È ren et al., 2000), and to play a role in the pathophysiology of malignant brain tumors (Roth et al., 2000) . The mechanism by which SFRP1 contributes to breast cancer progression through a loss of or a reduction in mRNA expression is currently unknown. Recent reports suggest that SFRP1 is proapoptotic in breast cancer cell lines (Melkonyan et al., 1997; Zhou et al., 1998) , suggesting that it plays an important role in breast cancer biology. Our data indicate that in breast tumors, SFRP1 loss does not seem to be associated with signi®cant changes in the overall rate of apoptosis. Loss of SFRP1 expression may unleash overactivity of the WNT pathway with overproduction of MYC and CCND1 proteins or other targets yet unknown. The exact role of SFRP1 in the multistep carcinogenesis of the mammary gland awaits further analysis and assessment of the in vivo function of the protein in normal, medullary, and preinvasive and invasive ductal epithelial breast cells.
Materials and methods
Clinical material
One hundred and eighteen unselected consecutive breast carcinoma samples (including cases from our preliminary study (Ugolini et al., 1999) ), i.e., three ductal carcinomas in situ, and 115 invasive (93 ductal, 13 lobular, four tubular, two mixed ductal and lobular, and three medullary) carcinomas were collected at Institut Paoli-Calmettes (Marseille, France). For subsequent analyses, a panel of 20 medullary carcinomas (using the criteria given by Ridol® et al., 1977) was collected including 17 typical and three atypical tumors. Tumors obtained from surgery were immediately frozen in liquid nitrogen, stored at 7708C and used in all methods. All tumor samples were reviewed by two independent pathologists, and classi®ed according to WHO recommendations. Ductal carcinomas in situ with or without invasive component when present in the tumors were graded as recommended by Shoker and Sloane (1999) .
One case of normal breast tissue from reduction mammoplasty from a non-menopausal young woman was selected for its correct content of epithelial component.
Clinicopathologic analysis
The clinical data and follow-up of 95 women included in this study with unilateral breast carcinoma (median age at diagnosis: 57 years; range: 26 ± 86), treated at Institut PaoliCalmettes (Marseille, France) were obtained from medical records. The following clinicopathological parameters were analysed: menopausal status, histological tumor size, axillary lymph node status, histologic grade (Elston and Ellis, 1991) , and histological features such as extensive intraductal component, and lymphoplasmocytic stroma graded as minimal or mild (1), moderate (2) or marked (3). The immunohistochemical investigation was done for hormonal receptors (estrogen and progesterone), proliferating index (by Ki-67 evaluation), P53, and BCL2 as previously described (Jacquemier et al., 1998) .
Statistical analysis
Correlations between SFRP1 expression and other prognostic factors were evaluated by the chi-square test, and reported as frequencies. Breast cancer-speci®c survival was calculated from the date of diagnosis, disease-related death being scored as an event, with censoring of other patients at the date of last follow-up or of non-disease-related death. Disease-free interval was also calculated from the date of diagnosis, ®rst recurrence (local or distant) being scored as an event, with censoring of other patients at the time of last follow-up or death. Local recurrence was de®ned as tumor arising in the treated breast.
Survival curves were estimated using the Kaplan and Meier estimates (1958) . Curves were compared by the log-rank test (Mantel, 1966) . Survival rates and risk are presented with their 95% con®dence intervals (CI).
Analysis of SFRP1 expression
The expression of SFRP1 was analysed by Northern blot and in situ hybridization (ISH).
Northern blot Hybridization using the SFRP1 probe corresponding to a 520-bp EcoRI/Notl fragment from yl57a10 cDNA clone, and result quanti®cations were done as described earlier (Ugolini et al., 1999 , and http:// olan.marseille.inserm.fr/pdf/ugolini99-1.pdf). Total normal breast RNA was from Clontech (Palo Alto, CA, USA).
Non-radioisotopic RNA in situ hybridization The riboprobes were obtained as follows: the pT7T3 plasmid containing a 1812 bp-long cDNA from the IMAGE clone yy11d03 from the German Human Genome Project Resource Center (RZPD, Berlin-Charlottenburg, Germany) was linearized with Notl or EcoRI for the antisense (positive) or sense (negative control) probes, respectively. The probes were digoxigenin-labeled using the Dig RNA labeling kit (Roche Diagnostics, Grenoble, France) according to the manufacturer's instructions. The breast cancer samples available were embedded in Tissue Freezing Medium (Jung), frozen in isopentane and liquid nitrogen, and then cryopreserved at 7808C until used. Cryocut sections of 12 mm were mounted on poly-L-lysinated slides, air-dried for 2 h at room temperature, ®xed in 4% paraformaldehyde in RNAse-free PBS (30 min), washed two times in PBS (30 min each), and processed immediately for the in situ experiment according to Philippe and Pollock (1998) . Sections were examined under a Zeiss microscope after methyl green staining. Immunohistochemical staining with myoepithelial cell markers (alpha smooth muscle actin and calponin) was then done in ductal carcinomas in situ. Toluidine blue staining was done for medullary tumors to check the cellularity of the lesion. In addition, for all samples, the normal duct/lobule component present in the sections was thoroughly examined.
In situ apoptotic cell labeling by the TUNEL method TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) was done by using in situ the cell death detection¯uorescein kit (Roche Molecular Biochemicals, Meylan, France) according to the manufacturer's instructions with slight modi®cations adapted from LabatMoleur et al. (1998) as follows: 6 mm thick frozen tumoral sections were ®xed in 4% paraformaldehyde in 0.01 M PBS (pH 7.4) for 20 min at room temperature (RT) followed by tissue pretreatment (0.1% Triton X-100 (Sigma Aldrich, St. Louis, MO, USA)), 0.1% sodium citrate (Merck, Darmstadt, Germany) for 2 min in ice followed incubation with proteinase K (0.3 mg/ml) in PBS for 20 min at 378C. Non-speci®c labeling was prevented by preincubating samples with 3% bovine serum albumin (BSA), 20% normal bovine serum (Jackson, West Grove, PA, USA) in PBS (pH 7.4) for 30 min at RT. The sections were then incubated for 1 h at 378C with TUNEL mix (calf thymus TDT,¯uorescein-dUTP in reaction buer as recommended by the supplier's instructions. After washings, the samples were then incubated in 3% BSA and 20% normal sheep serum (Sigma Aldrich) in 1% blocking reagent (Roche Molecular Biochemicals) for 30 min at RT. They were then treated with alkaline phosphate-conjugated sheep anti-¯uor-escein antibody (Roche Molecular Biochemicals) as recommended followed by washing and Fast red staining (Dako's kit). Sections were observed under a light microscope (original magni®cation6200) after Meyer's hematoxylin color reaction, and Merckoglas (Merck) mounting.
Staining analyses were correlated with apoptotic morphology as described (Gold et al., 1993) with modi®cations by Labat-Moleur et al. (1998) . Brie¯y, three features were considered to represent apoptosis: marked condensation of chromatin and cytoplasm (apoptotic cells), cytoplasmic fragments with or without condensed chromatin (apoptotic bodies), and intra-and extracellular chromatin fragments (micronuclei). Semi-quantitative analysis was done by estimation of an apoptotic index [number of apoptotic cells (6200)/ tumor cell density)] in non-necrotic areas and was classi®ed within four range values: 0 ± 1% of labeled cells; 1 ± 10%; 10 ± 30%; 30 ± 60%.
